

AstraZeneca Building
 AstraZeneca Building
 AstraZeneca Building

DUBAI, UNITED ARAB EMIRATES,
 February 20, 2024 /EINPresswire.com/
 -- (ARAB NEWSWIRE)



AstraZeneca Building

AstraZeneca Building
 AstraZeneca Building
 AstraZeneca Building

- AstraZeneca Building
 AstraZeneca Building
 AstraZeneca Building

AstraZeneca Building
 AstraZeneca Building
 AstraZeneca Building

- AstraZeneca Building
 AstraZeneca Building
 AstraZeneca Building

o 000 00000000 00000 000 00000 000000 00000000 FLAURA2 00000000 00 0000 000 00000000 0000000 (The New England Journal of Medicine)0 00000 000000 00 000000 00000000 000000000000 000 000000000 000 00 000 00000 000000 00 00000000 000000 38% 00000000 000000 000000000 00000 00000 00000 00000 000000000 00 000000000 000000000.

- 00 0000 0000 0000 00 000000000000 000000000000 (Dato-DXd) 00000 00 0000000
00000000 000 000000000000 00000000 0000000 0000000 0000 0000000 00 00000000 00000000
0000000000

-□□□□□□□-

000000000000 (LSE/STO/Nasdaq: AZN) 00 0000 000000 00000 00 0000 00000000 00000000 0000
 000 0000000 0000000 00000000 00000000 00000000 00 000000 00000000 000000000 00000000
 000000000 000000000 000 00 000 00000000 00000000 000000000 0000000 00000000 000000000.
 000000 00 00000000000 00000000 000000000 0000 0000000000000 00 0000 00 100 000000 00000000
 000000000 0000000000 00 000 0000000 0000000 0000 00000000. 00000 000000 astrazeneca.com
 000000000 00000000 0000 000000 @AstraZeneca.

タスク（osimertinib）は EGFR-TKI の一種で、EGFR が過剰発現している NSCLC の患者に有効です。タスク（osimertinib）は、EGFR が過剰発現している NSCLC の患者に有効です。タスク（osimertinib）は、EGFR が過剰発現している NSCLC の患者に有効です。

0000 000 0000 00 000000 0000 0000000 0000000 00 00000 00000 000 0000 0000000
(NSCLC) 0000000 0000000 0000000 (EGFR). 0000000 00 000000 000000000 0000000 0000 0000

ADURA
FLAURA
FLAURA2.

SAVANNAH ORCHARD
SAFFRON
MET TKI

(gefitinib) (durvalumab) (tremelimumab) (trastuzumab deruxtecan) (savolitinib) HUTCHMED

mediamea@astrazeneca.com

(www.arabnewswire.com) –
(MENA) –
EmailWire™ (www.emailwire.com) –

Chloe Jolley
AstraZeneca
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/689951632>
EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

